GTS‑21
Experimental nootropic developed for the thinking problems of schizophrenia; not proven in people, and the results were inconsistent.
Pharmacology
Contents
DETAILED OVERVIEW
What is GTS-21?
GTS-21 (also known as DMXB-A) is an experimental compound, a synthetic derivative of anabaseine, a marine toxin. It is not approved as a medicine anywhere and exists only as a research compound. It was originally developed to improve the attention and thinking problems that go with schizophrenia.
It partly switches on one of the brain's nicotinic receptors (alpha-7), which helps regulate attention, working memory and the filtering of incoming stimuli. Small, early-phase studies were done in healthy volunteers and in people with schizophrenia. In schizophrenia it improved this filtering, but its effect on thinking was inconsistent, partly because the substance breaks down quickly and its blood level fluctuates. Its benefit in people is therefore not proven; in animals it improved learning and memory. It can cause nausea and headache, its long-term safety in humans is unclear, and its safety in pregnancy and breastfeeding has not been established.
Mechanism
α7 nAChR partial agonist
Evidence
Phase 2 human trials (not approved)
Legal status
Experimental, unapproved drug
No anecdote collected yet.
Receptor profile
- Alpha-7 nicotinic acetylcholine receptor (α7 nAChR)Strong
- Glutamatergic / dopaminergic signaling (indirect)Moderate
- Cholinergic anti-inflammatory pathway (NF-κB suppression)Moderate
- Alpha-4-beta-2 nicotinic receptor (weak antagonism)Weak
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Gastrointestinal complaints: nausea, abdominal discomfort, occasional vomiting at higher doses
- Headache and dizziness reported in human trials
- Short half-life and an active metabolite (4-OH-GTS-21) cause fluctuating plasma levels and effect
- Efficacy was inconsistent across phase 2 trials: cognitive benefit was not always confirmed
- Long-term safety in humans is unclear; there is no approved therapeutic use
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Unapproved experimental compound; not recommended without clinical supervision
- Active gastrointestinal disease: nausea and GI effects may aggravate it
- Unknown interaction profile: caution with cholinergic and psychoactive agents
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers
Kitagawa H, Takenouchi T, Azuma R, et al.
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia
Olincy A, Harris JG, Johnson LL, et al.
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman R, Olincy A, Buchanan RW, et al.
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia
Tregellas JR, Tanabe J, Rojas DC, et al.
Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia
Kem WR, Olincy A, Johnson L, et al.
FAQ
FAQ
GTS-21 is an experimental compound, a synthetic relative of a marine-organism toxin, that targets a specific brain receptor involved in attention and working memory. In small, early-stage human trials it improved sensory filtering in people with schizophrenia, and in animal studies it showed learning and memory benefits along with nerve-protective effects. This is fundamentally a research-stage substance with a moderate amount of early human data, not an established, widely used nootropic.
Telegram
Have a question about GTS‑21?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.